---
title: 'Fibroblast Activation Protein-Directed Imaging Outperforms <sup>18</sup>F-FDG
  PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial'
date: '2024-07-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38960716/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240704182753&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'The fibroblast activation protein (FAP) is highly expressed in tumor
  and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic
  target. Previous data on PET imaging with radiolabeled FAP inhibitors (FAPIs) suggest
  high potential for superior tumor detection. Here, we report the data of a large
  malignant pleural mesothelioma cohort within a ^(68)Ga-FAPI46 PET observational
  trial (NCT04571086). Methods: Of 43 eligible patients with suspected or proven ...'
disable_comments: true
---
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with radiolabeled FAP inhibitors (FAPIs) suggest high potential for superior tumor detection. Here, we report the data of a large malignant pleural mesothelioma cohort within a ^(68)Ga-FAPI46 PET observational trial (NCT04571086). Methods: Of 43 eligible patients with suspected or proven ...